← Leaderboards
Alexi A Wright
Dana-Farber Cancer Inst
$5,090,186
Attributed
$6,787,687
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,787,687 · 6
By mechanism
R01$5,023,988 · 3
K07$885,600 · 1
R21$878,099 · 2
Top collaborators
- Joanna J Arch2 shared
- Andrea C Enzinger2 shared
- Jukka-Pekka Onnela2 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Andrea C Enzinger$2,832,837
- Avinash Das Sahu$955,886
- Michael James Hassett$3,146,811
Others in their field
Top investigators on “Cancer Patient”
- David Heimbrook · Leidos Biomedical Research, Inc.$436,176,488
- Larry Arthur$370,429,903
- Norman Wolmark · Nsabp Foundation, Inc.$324,028,859
- Gregory H Reaman · National Childhood Cancer Foundation$270,366,096
- Leonard Freedman · Leidos Biomedical Research, Inc.$268,085,841
- Richard A Gibbs · Baylor College Of Medicine$240,560,484
Research focus
Cancer PatientDistressMalignant NeoplasmsCaringQuality Of LifeAdvanced Malignant NeoplasmCaregiversHealthcareEnd Of LifeCessation Of LifeMedicalMonitorTherapy DesignReportingBaseBehaviorMalignant Neoplasm Of OvaryLifeMhealthCopingHigh RiskCancer CareMalignant Neoplasm Of Gastrointestinal TractHospice Environment
Grant awards (16)
Variability in Opioid Prescribing Across the Cancer Care Continuum: A Multi-Level Analysis$726,540
R01 · FY2025 · CA
Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors$685,764
R01 · FY2025 · CA · contact PI
BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial$683,515
R01 · FY2025 · CA · contact PI
A multi-level examination of the influences of racism on cancer pain equity$775,031
R01 · FY2024 · CA
Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors$748,174
R01 · FY2024 · CA · contact PI
BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial$663,577
R01 · FY2024 · CA · contact PI
BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial$741,387
R01 · FY2023 · CA · contact PI
Passive Data to Improve Outcomes in Advanced Cancer$252,812
R21 · FY2020 · NR · contact PI
Strengthening Patient and Caregiver Supports in Ovarian Cancer with Palliative Care: Pilot RCT of BOLSTER$228,191
R21 · FY2020 · CA · contact PI
Passive Data to Improve Outcomes in Advanced Cancer$206,682
R21 · FY2019 · NR · contact PI
Strengthening Patient and Caregiver Supports in Ovarian Cancer with Palliative Care: Pilot RCT of BOLSTER$190,414
R21 · FY2019 · CA · contact PI
Chemotherapy Near Death: Modifiable Factors and Outcomes in Ovarian Cancer$177,120
K07 · FY2017 · CA · contact PI
Chemotherapy Near Death: Modifiable Factors and Outcomes in Ovarian Cancer$177,120
K07 · FY2016 · CA · contact PI
Chemotherapy Near Death: Modifiable Factors and Outcomes in Ovarian Cancer$177,120
K07 · FY2015 · CA · contact PI
Chemotherapy Near Death: Modifiable Factors and Outcomes in Ovarian Cancer$177,120
K07 · FY2014 · CA · contact PI
Chemotherapy Near Death: Modifiable Factors and Outcomes in Ovarian Cancer$177,120
K07 · FY2013 · CA · contact PI